石大勝華(603026.SH):擬投資12.8億元建22萬噸/年鋰電材料生產研發一體化項目
格隆匯12月2日丨石大勝華(603026.SH)公佈,公司全資子公司擬投資建設22萬噸/年鋰電材料生產研發一體化項目(12萬噸/年碳酸乙烯酯、5萬噸/年碳酸二甲酯、4.5萬噸/年碳酸甲乙酯、0.5萬噸/年碳酸二乙酯)。項目預計總投資128263.29萬元,項目建設地為湖北省武漢市化學工業園,廠區佔地面積為111647.39㎡。
目前公司碳酸酯類產品正常生產和銷售,鋰電材料生產研發一體化項目的建設是公司多基地佈局的戰略需要。公司充分發揮在碳酸酯溶劑領域的技術優勢,增加利潤增長點,提升公司行業內的影響力,促進企業競爭力的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.